Myelodysplastic Syndromes (MDS) Research Study
|
Alemtuzumab (Campath-1H) for Myelodysplastic Syndrome (MDS)
|
Hematologists at the National Heart, Lung, and Blood Institute are investigating a new treatment for myelodysplastic syndrome (MDS). The study drug, a monoclonal antibody, may help increase blood counts, reduce anemia symptoms, and/or reduce dependence on transfusions. If eligible to participate, consenting subjects will receive an intravenous infusion of study medication alemtuzumab (Campath-1H) once a day for 10 days. Subjects will be admitted to the NIH Clinical Center hospital for study drug initiation. If the study drug infusion is tolerated well, the subject may be discharged and receive the remainder of the treatment course as an outpatient.
If you have been diagnosed with MDS and are 18 years or older, you may be able to participate in this clinical trial. To find out if you qualify, please call our study coordinator at 301-594-4180 or email us at BloodStudy@nhlbi.nih.gov
|
|
 
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Myelodysplastic Syndromes (MDS) Research Study
|
Escalating Doses of ON 01910.Na for Myelodysplastic Syndrome (MDS)
|
If you are between the ages of 18 and 85 and have been diagnosed with Myelodysplastic Syndrome (MDS), you may be able to participate in a clinical trial evaluating a new experimental anti-cancer therapy. This study will determine what dose and which dosing schedule of this new drug is safe. We will also evaluate whether or not this drug can slow progression of your illness, improve blood counts, and/or reduce the need for transfusions of blood and/or platelets.
Study participants will receive 3-5 days of drug infusion ( 1 cycle) every other week for a minimum of 2 cycles and a maximum of 8 cycles.
To find out if you qualify or for more information, please contact our study coordinator at 301-594-4180 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Myelodysplastic Syndromes (MDS) Research Study
|
Non-myeloablative stem cell transplant for patients with myelodysplastic syndrome
|
If you have been diagnosed with MDS, you may be able to participate in a stem cell transplant clinical trial designed to evaluate methods to decrease graft versus host disease, promote engraftment, and improve immune system recovery following a bone marrow stem cell transplant procedure.
You must have an HLA-matched family member to participate. You will be given chemotherapy followed by a transfusion of stem cells and lymphocytes from your donor, which will replace your immune system with the immune system of your healthy donor. Post transplant therapy is designed to reduce the risk of graft versus host disease.
We do the blood testing free of charge to see if your family member is a match. We pay for all medical costs related to the transplant procedure. You must be available to live near NIH for approximately 3 months. We also provide a daily allowance to help with living expenses while you are on the study and living away from home.
To inquire about eligibility, contact our research coordinator at (301) 594-8013 or by e-mail BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Myelodysplastic Syndromes (MDS) Research Study
|
Selectively Depleted Stem Cell Transplant to Treat Myelodysplastic Syndrome (MDS)
|
If you (or someone you know) have been diagnosed with Myelodysplastic syndrome, you may be able to participate in our clinical trial designed to investigate methods of making stem cell transplant procedures safer and more effective. Specifically, we are testing whether the special treatment of donor stem cells and immune cells will reduce complications (Graft versus host disease) and improve transplant outcome. You must have an HLA matched brother or sister who is willing to participate as a donor in order to participate in this study.
To find out if you qualify, please contact our research coordinator at (301) 496-3841 or by email at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Myelodysplastic Syndromes (MDS) Research Study
|
Stem Cell Transplant to Treat Myelodysplastic Syndrome (MDS)
|
If you (or someone you know) have been diagnosed with Myelodysplastic Syndrome, you may be able to participate in our clinical trial designed to investigate methods of making stem cell transplant procedures safer and more effective. Specifically, we are testing whether special treatment of donor stem cells and delaying the transfusion of donor immune cells will reduce complications and improve transplant outcome. You must have an HLA-matched brother or sister who is willing to participate as a donor in order to participate in this study.
To find out if you qualify, please contact our research coordinator at (301) 496-3841 or by email at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Myelodysplastic Syndromes (MDS) Research Study
|
Umbilical Cord Transplant to Treat Myelodysplastic Syndrome (MDS)
|
If you (or someone you know) has been diagnosed with myelodysplastic syndrome, you may be able to participate in our clinical trial designed to investigate methods of making stem cell transplant procedures safer and more effective for a wide number of diseases and disorders. In this study, we will evaluate the safety and effectiveness using a different type of stem cell transplant procedure, specifically, co-infusion of peripheral blood stem cells from a family member and cord blood stem cells from an unrelated donor.
You must have a family member who is willing to participate as a stem cell donor as well as the availability of an HLA matched umbilical cord blood unit (the NIH will conduct the search and procurement) in order to participate in this study.
To find out if you qualify, please contact our research coordinator at (301) 594-8013 or by email at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Myelodysplastic Syndromes (MDS) Research Study
|
WT1 + PR1 peptide vaccine for myelodysplastic syndrome (MDS)
|
If you are 18 years old or older and have been diagnosed with MDS, you may be able to participate in a clinical trial evaluating a new vaccine therapy. We believe your immune system might be able to control the abnormal growth of cells that is causing your MDS. This study will test whether vaccination with a WT1 peptide and a PR1 peptide may increase the number of immune cells responding to your MDS and thereby slow progression of your illness, improve blood counts, reduce the need for transfusions of blood and platelets, or even achieve a remission for your MDS. Consenting subjects will receive one dose of WT1 vaccine and one dose of PR1 vaccine every other week for 12 weeks (total of 6 vaccinations) followed by post vaccination evaluations 2 weeks and 4 weeks after the last dose of the vaccines.
To find out if you qualify or for more information, please contact our study coordinator at 301-496-3841 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Myelodysplastic Syndromes (MDS) Research Study
|
WT1 peptide vaccine study for myelodysplastic syndrome (MDS)
|
If you are 18 years old or older and have been diagnosed with MDS, you may be able to participate in a clinical trial evaluating a new therapy. We believe your immune system might be able to control the abnormal growth of cells that is causing your MDS. This study will test whether vaccination with a WT-1 peptide may increase the number of immune cells responding to your MDS and thereby slow progression of your illness, improve blood counts, reduce the need for transfusions of blood and platelets, or even achieve a remission for your MDS. Consenting subjects will receive two intravenous infusion of fludarabine at the NIH followed by vaccination with a WT1 peptide once a week for 9 weeks followed by monthly follow up evaluations.
To find out if you qualify or for more information, please contact our study coordinator at 301-496-3841 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
|
|
Department of Health
and Human Services
National
Institutes of Health
National Heart, Lung, and Blood
Institute